ClinicalTrials.gg

Tuberculosis, Pulmonary clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 319 studies for Tuberculosis, Pulmonary across more than 10 countries. 71 are recruiting or about to start. 268 of them are mainly about Tuberculosis, Pulmonary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
174
Recruiting
46
Status unknown
42
Not yet recruiting
23
Active, not recruiting
11
Terminated
10

Phase

Phase 2
95
Phase 3
45
Phase 1
28
Phase 4
16
Early Phase 1
2

Where

South Africa
78
China
28
India
26
United States
26
Uganda
24
Tanzania
17

Who develops what

Add Tuberculosis, Pulmonary to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bedaquilineRecent, limited
Evidence
  • NCT05824871 · Shanghai Jiatan Pharmatech Co., Ltd · Phase 3 · live · comparator · “Bedaquiline” · registered Apr 2023
  • NCT04608955 · Shanghai Jiatan Pharmatech Co., Ltd · Phase 2 · comparator · “Bedaquiline” · registered Oct 2020
  • NCT04550832 · LigaChem Biosciences, Inc. · Phase 2 · background · “Bedaquiline, Delamanid, Moxifloxacin” · registered Sep 2020
Johnson & Johnson69% of its industry studiesUS: JANSSEN THERAP (FDA 2012)11 study
LinezolidRecent, limited
Evidence
  • NCT05382312 · GlaxoSmithKline · Phase 2 · background · “Linezolid” · registered May 2022
  • NCT02836483 · LigaChem Biosciences, Inc. · Phase 2 · comparator · “Zyvox 600mg, BID” · registered Jul 2016
Pfizer78% of its industry studiesUS: off-patent, 16 generics marketed11 study
MoxifloxacinRecent, limited
Evidence
  • NCT05382312 · GlaxoSmithKline · Phase 2 · background · “Moxifloxacin” · registered May 2022
  • NCT04550832 · LigaChem Biosciences, Inc. · Phase 2 · background · “Bedaquiline, Delamanid, Moxifloxacin” · registered Sep 2020
Bayer20% of its industry studiesUS: off-patent, 14 generics marketed11 study

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Tuberculosis, Pulmonary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Statins 3 open · Beta-lactamase inhibitors 1 open

Coming up

26studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger. 11 (24%) take children under 18. 0 (0%) are for women only and 1 (2%) for men only; 7 (15%) take healthy volunteers.

Recruiting studies that take each age, of 46
AgeWomenMen
106 (13%)6 (13%)
1839 (85%)39 (85%)
3039 (85%)40 (87%)
4040 (87%)41 (89%)
5039 (85%)40 (87%)
6539 (85%)39 (85%)
7526 (57%)26 (57%)
8524 (52%)24 (52%)

Across all 319 studies, recruiting or not: 42% stop at 75 or younger and 34% at 65; 22% take children; 1% are for women only and 2% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Tuberculosis, Pulmonary studies take

Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 13 mo2–13 · 13 studies——
Phase 230 mo21–37 · 43 studies—30 mo21–49 · 33 studies
Interventional, no phase17 mo11–29 · 42 studies—17 mo11–29 · 42 studies
Observational32 mo21–49 · 45 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 319. Browse all 319 → or search them.